Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease worldwide, affecting over 38% of the global population, and imposing profound clinical and economic burdens. While its pathogenesis is multifactorial, genetic predisposition plays a critical role, with recent genome-wide association studies identifying variants in multiple genes, including fat mass and obesity-associated (FTO). FTO functions as a central regulator of energy homeostasis, adipogenesis, and lipid metabolism through its ability to modulate messenger RNA (mRNA) methylation. The role of FTO in obesity, body fat composition, type 2 diabetes and insulin resistance has been extensively discussed. Nevertheless, the role of FTO in MASLD has been scarcely demonstrated. Increasing evidence links FTO to hepatic lipid accumulation, impaired fatty acid oxidation, mitochondrial dysfunction, and inflammatory signalling, positioning it as a key player in MASLD pathogenesis. Moreover, allele-specific associations underscore its contribution to inter-individual differences in disease susceptibility and progression. In this review, we summarize current mechanistic evidence on the direct and indirect roles of FTO in MASLD, highlight its impact on metabolic and inflammatory pathways, and discuss the therapeutic potential of targeting FTO in the context of precision medicine, especially with the limited treatment options.
No takes yet. Share an insight, caveat, or question.
Kassem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: